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Alison Goate, Ph.D., Nick C. Fox, M.D., Daniel S. Marcus, Ph.D., Nigel J. Cairns, Ph.D., Xianyun Xie, M.S.,
Tyler M. Blazey, B.S., David M. Holtzman, M.D., Anna Santacruz, B.S., Virginia Buckles, Ph.D., Angela Oliver, R.N.,
Krista Moulder, Ph.D., Paul S. Aisen, M.D., Bernardino Ghetti, M.D., William E. Klunk, M.D., Eric McDade, M.D.,
Ralph N. Martins, Ph.D., Colin L. Masters, M.D., Richard Mayeux, M.D., John M. Ringman, M.D.,
Martin N. Rossor, M.D., Peter R. Schofield, Ph.D., D.Sc., Reisa A. Sperling, M.D., Stephen Salloway, M.D.,
and John C. Morris, M.D., for the Dominantly Inherited Alzheimer Network

A BS T R AC T
BACKGROUND

The order and magnitude of pathologic processes in Alzheimer’s disease are not well
understood, partly because the disease develops over many years. Autosomal dominant Alzheimer’s disease has a predictable age at onset and provides an opportunity
to determine the sequence and magnitude of pathologic changes that culminate in
symptomatic disease.
METHODS

In this prospective, longitudinal study, we analyzed data from 128 participants who
underwent baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. We used the participant’s age at baseline assessment and the parent’s age at the onset of symptoms of Alzheimer’s disease to calculate the estimated years from expected symptom onset (age of the participant minus
parent’s age at symptom onset). We conducted cross-sectional analyses of baseline
data in relation to estimated years from expected symptom onset in order to determine the relative order and magnitude of pathophysiological changes.
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RESULTS

Concentrations of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before
expected symptom onset. Aβ deposition, as measured by positron-emission tomography with the use of Pittsburgh compound B, was detected 15 years before expected
symptom onset. Increased concentrations of tau protein in the CSF and an increase
in brain atrophy were detected 15 years before expected symptom onset. Cerebral
hypometabolism and impaired episodic memory were observed 10 years before expected symptom onset. Global cognitive impairment, as measured by the Mini–Mental
State Examination and the Clinical Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at
an average of 3 years after expected symptom onset.
CONCLUSIONS

We found that autosomal dominant Alzheimer’s disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of
Alzheimer’s disease, brain amyloid deposition, and brain metabolism as well as
progressive cognitive impairment. Our results require confirmation with the use of
longitudinal data and may not apply to patients with sporadic Alzheimer’s disease.
(Funded by the National Institute on Aging and others; DIAN ClinicalTrials.gov
number, NCT00869817.)
n engl j med 367;9
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A

lzheimer’s disease is the most common cause of dementia and is currently
estimated to affect more than 5 million
people in the United States, with an expected increase to 13 million by the year 2050. The typical
clinical presentation is progressive loss of memory and cognitive function, ultimately leading to
a loss of independence and causing a heavy personal toll on the patient and the family. The costs
of care of patients with Alzheimer’s disease in
2010 were estimated at more than $172 billion in
the United States, an annual cost that is predicted to increase to a trillion dollars by 2050 unless
disease-modifying treatments are developed.1
Alzheimer’s disease has been hypothesized to
begin decades before the first symptoms manifest.2-4 Thus, longitudinal studies of Alzheimer’s
disease biomarkers take many years to show the
full pathologic cascade of events that lead to dementia. Furthermore, trials of disease-modifying
treatment require large numbers of patients over
extended periods owing to the slow progression of
cognitive symptoms.5,6 Therefore, well-validated
biomarkers of Alzheimer’s disease processes are
needed to improve the design of clinical trials,
develop more effective therapeutics, and offer the
opportunity for prevention trials.7
On the basis of the amyloid hypothesis,8
amyloid-beta (Aβ) is currently the most common
disease-modifying target. Recent research indicates that the targeting of amyloidosis in familial
amyloid polyneuropathy improves clinical outcomes.9-11 However, the order and timing of amyloidosis and other Alzheimer’s disease processes
that lead to clinical dementia are not well understood. We hypothesized that autosomal dominant Alzheimer’s disease and the more common
late-onset Alzheimer’s disease12 have similar
pathophysiological features. Although autosomal
dominant Alzheimer’s disease accounts for a
relatively small proportion (approximately 1%) of
cases of Alzheimer’s disease, increasing evidence13
suggests that it overlaps with sporadic Alzheimer’s
disease. Mutations in one of three genes (APP,
PSEN1, and PSEN2) have been identified that cause
alterations in Aβ processing and lead to Alzhei
mer’s disease with complete penetrance. The age at
clinical onset of autosomal dominant Alzheimer’s
disease is similar between generations14 and is
affected mostly by the mutation type and background family genetics.15 We compared a wide
range of pathophysiological markers between mutation carriers and noncarriers as a function of
796
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the parental age at onset in order to evaluate the
cascade of events that lead to dementia. Clinical,
cognitive, imaging, and biochemical measures
were compared between mutation carriers and
noncarriers in the first large international cohort
of families with autosomal dominant Alzheimer’s
disease.

Me thods
STUDY DESIGN

Participants at risk for carrying a mutation for
autosomal dominant Alzheimer’s disease were
enrolled in the Dominantly Inherited Alzheimer
Network (DIAN) study at 1 of 10 sites. Each participant was a member of a pedigree with a known
mutation for autosomal dominant Alzheimer’s
disease. DIAN participants are assessed at baseline and in subsequent years with comprehensive
clinical, cognitive, imaging, and biochemical assessments. Data from all 128 participants who
were enrolled and who had completed baseline
assessments between January 26, 2009, and the
first data-cutoff point (April 28, 2011) went through
quality-control checks and were included in the
analysis (see the Methods section in the Supplementary Appendix, available with the full text of
this article at NEJM.org). All participants provided
written informed consent or assent with proxy consent. All study procedures were approved by the
Washington University Human Research Protection Office and the local institutional review boards
of the participating sites. All authors vouch for the
accuracy of the data and the fidelity of the study to
the protocol (available at NEJM.org).
CLINICAL ASSESSMENTS

Participants underwent clinical assessments of
cognitive change with the use of the Clinical Dementia Rating (CDR)16 scale, with CDR 0 indicating normal cognitive function, CDR 0.5 very mild
impairment, and CDR 1 mild impairment. The
DIAN assessments ascertained family history of
Alzheimer’s disease and medical history, and participants underwent a physical examination, including a neurologic evaluation (see the study
protocol). Clinicians who performed the assessments were not aware of the mutation status of
participants. The parental age at onset was determined by a semistructured interview in which
family members were asked about the age of first
progressive cognitive decline (Fig. S1 in the Supplementary Appendix). Clinical feedback was
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provided to participants if medically indicated.
No other research data, including genetic status,
were provided to research participants as part of
the study.

Table 1. Characteristics of the Study Participants.*
Characteristic
Age — yr

NEUROPSYCHOLOGICAL TESTING

Male sex — no. (%)

Carriers
(N = 88)

Noncarriers
(N = 40)

P Value

39.1±10.3

39.5±8.9

0.92

36 (41)

17 (42)

0.85

Participants underwent a comprehensive battery
Education level — yr
13.9±2.5
15.0±2.5
0.04
of neuropsychological tests, but results of only
Cognitive status — no. (%)†
two tests are reported here because of space limSymptomatic
43 (49)
1 (2)
0.29
itations; both tests are widely used in research on
Asymptomatic
45 (51)
39 (98)
Alzheimer’s disease. The Mini–Mental State Ex17
Positive
for
apolipoprotein
E
22
(25)
9 (22)
0.69
amination (MMSE) is a measure of general cogε4 allele — no. (%)
nitive function, with scores ranging from 0 (severe impairment) to 30 (no impairment). Story A * Plus–minus values are means ±SD.
from the Logical Memory subtest of the Wechsler † Participants were defined as asymptomatic if they had Cognitive Dementia
Rating scores of 0 (no cognitive decline) and as symptomatic if they had
Memory Scale–Revised18 is a measure of episodic
scores greater than 0.
memory. Participants recall as many details as they
can from a short story containing 25 bits of information after it is read aloud by the examiner and the DIAN biomarker core laboratory. Concentraagain after a 30-minute delay, with scores rang- tions in the CSF of Aβ1-42, total tau, and tau
ing from 0 (no recall) to 25 (complete recall).
phosphorylated at threonine 181 were measured
by immunoassay (INNOTEST β-Amyloid1-42 and
BRAIN IMAGING
INNO-BIA AlzBio3, Innogenetics), as were levels
Volumetric magnetic resonance imaging (MRI) of plasma Aβ species (Aβ1-40, Aβ1-42, Aβx-40, and
was performed with the use of qualified 3-tesla Aβx-42) (INNO-BIA Plasma Aβ Forms Multiplex
scanners at each site; initial and ongoing quality Assay, Innogenetics). All values had to meet
control and matching between site scanners were quality-control standards, including a coefficient
performed according to the Alzheimer’s Disease of variation of 25% or less, kit “controls” within
Neuroimaging Initiative (ADNI) protocol.19 All the expected range as defined by the manufacimages were reviewed for image quality and com- turer, and measurement consistency between
pliance with the acquisition protocol by the ADNI plates of a common sample that was included in
imaging core laboratories. The T1-weighted MRI each run.
scans from DIAN participants were processed
through FreeSurfer (for details, see the Supplemen- STATISTICAL ANALYSIS
tary Appendix). Images obtained through positron- The estimated years from expected symptom onemission tomography (PET) with the use of fluo- set were calculated as the age of the participant
rodeoxyglucose (FDG) and Pittsburgh compound B at the time of the study assessment minus the
(PIB) (FDG-PET and PIB-PET, respectively) were age of the parent at symptom onset. For example,
then coregistered with individual MRI images if the participant’s age was 35 years, and the parfor region-of-interest determination. For each ent’s age at onset was 45 years, then the estiFreeSurfer region of interest, the standardized mated years from expected symptom onset would
uptake value ratio (SUVR) was calculated with be −10. The parental age at the onset of clinical
the use of a hand-drawn reference region en- symptoms was determined by a semistructured
compassing the brain stem. An increased PIB interview with the use of all available historical
SUVR indicates increased binding to fibrillar data (Fig. S1 in the Supplementary Appendix).
amyloid, and a decreased FDG SUVR indicates Clinical, cognitive, imaging, and biochemical
decreased metabolism.
measures were compared as a function of estimated years from expected symptom onset beBIOCHEMICAL ANALYSIS
tween mutation carriers and noncarriers. StatisCerebrospinal fluid (CSF) and blood were collect- tical analyses (see the Supplementary Appendix
ed in the morning under fasting conditions by for details) were conducted with the use of the
means of lumbar puncture and venipuncture, re- PROC MIXED procedure in SAS software, version
spectively. Samples were shipped on dry ice to 9.3 (SAS Institute). With each marker treated as a
n engl j med 367;9
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continuous scale, a linear mixed model was used
to model each marker as a function of estimated
years from expected symptom onset, mutation
status (carrier or noncarrier), and apolipoprotein
E (APOE) status (positive or negative). Approximate Student’s t-test results derived from the
model were used to determine whether marker
values differed between mutation carriers and
noncarriers at certain age points (Table S4 in the
Supplementary Appendix), after adjustment for
the correlation among family members. Values
for individual participants were not displayed on
graphs to protect the confidentiality of the mutation status of participants (e.g., a participant
who did not know his or her mutation status
could deduce it from individual values of estimat-

of

m e dic i n e

ed years from expected symptom onset). Figure 2
was generated with the same final models, with
the use of the standardized difference between
mutation carriers and noncarriers as a function
of estimated years from expected symptom onset
— that is, the predicted difference at each estimated year from expected symptom onset divided by the standard deviation for clinical, cognitive, imaging, and biochemical measures.

R e sult s
STUDY PARTICIPANTS

We analyzed 128 participants from the DIAN cohort (Table 1). The mutation types reflected the distribution of mutations described in the literature,

Table 2. Clinical, Cognitive, Imaging, and Biochemical Estimates in Mutation Carriers and Noncarriers.*
Variable

Estimated Years from Expected Symptom Onset
−25

−20

−15

−10

−5

0

5

10

0

0

0

0

0

0

0

0

CDR-SOB score (no.)†
Noncarriers
Carriers
Difference

0

0

0.2

0.7

1.5

0.2±1.1

0.7±1.1

1.5±1.1‡

2.6

29.5

29.5

29.5

29.6

29.6

29.6

29.7

29.7

29.1

28.1

26.5

24.6

22.1

19.3

−1.4±1.9

−3.1±2.0‡

−5.0±2.0§

15.1

13.9

12.5

11.3

10.8

11.7

14.1

11.4

8.3

5.2

2.8

1.4

2.6±1.1§

4.0
4.0±1.3§

5.7

0±2.2

0±1.4

5.7±1.7§

Noncarriers

29.4

Carriers

29.9
0.5±4.0

0.2±2.5

Noncarriers

14.7

15.6

Carriers

16.3

15.9

1.6±4.2

0.3±2.7

Noncarriers

0.69

0.69

0.69

0.70

0.70

0.69

0.68

0.67

Carriers

0.71

0.76

0.9

1.08

1.24

1.36

1.38

1.24

MMSE score (no.)¶

Difference

−0.4±1.9

−7.5±2.2§ −10.4±3.1§

Logical Memory score (no.)‖

Difference

−1.0±2.0

−2.5±2.0** −4.2±2.2§

−6.1±2.2§

−8.0±2.5§ −10.3±3.7§

Aβ deposition in the precuneus
(SUVR ratio)††

Difference

0.02±0.28 0.07±0.17 0.21±0.15‡ 0.38±0.13§ 0.54±0.12§

0.67±0.15§

0.70±0.17§ 0.57±0.21§

Glucose metabolism in the precuneus
(SUVR ratio)‡‡
Noncarriers

2.06

2.04

2.01

1.99

1.97

1.95

1.92

1.90

Carriers

2.16

2.05

1.94

1.83

1.72

1.61

1.50

1.39

Difference

0.10±0.16 0.01±0.13 −0.07±0.11 −0.16±0.09§ −0.25±0.08§ −0.34±0.09§ −0.42±0.12§ −0.51±0.15§

Total hippocampal volume (mm3)
Noncarriers

8999

8874

8748

8622

8497

8371

8245

8120

Carriers

8767

8511

8255

7999

7743

7486

7230

6974

Difference

798

−232±675 −363±548 −493±442** −623±370‡ −754±356§
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Table 2. (Continued.)
Variable

Estimated Years from Expected Symptom Onset
−25

−20

−15

−10

−5

0

5

10

454

436

421

410

402

398

397

399

210

219

Aβ42 in the CSF (pg/ml)
Noncarriers
Carriers
Difference

532

433

78±149

−3±97

352
−69±82

289
−121±85‡

245
−157±88§

218
−180±90§

−187±107‡ −180±155**

Tau in the CSF (pg/ml)
Noncarriers
Carriers

39

41

42

44

45

47

50

35

55

76

97

117

159

179

−4±52

14±41

34±33**

53±27§

72±27§

91±31§

111±39§

129±50§

Noncarriers

37.0

34.8

33.1

31.7

30.8

30.3

30.2

30.5

Carriers

42.4

41.8

41.6

41.9

42.5

43.5

45.0

46.9

11.7±5.8§

13.2±6.8§

14.8±8.5§

16.4±10.5§

Difference

138

48

Plasma Aβ42 (pg/ml)

Difference

5.4±10.8

7.0±8.7

8.5±7.0** 10.2±6.0‡

*		 The timing of assessments was defined on the basis of the estimated years from expected symptom onset, calculated as the age of the
participant at assessment minus the age of the parent at symptom onset. Estimates are reported with 95% confidence intervals for the
difference between mutation carriers and noncarriers. Estimates were obtained with use of a mixed model that treated mutation status
(noncarrier or carrier), estimated year from expected symptom onset (or higher-order term), and interactions between mutation status
and estimated year from expected symptom onset as covariates regardless of the participant’s score on the Clinical Dementia Rating–
Sum of Boxes (CDR-SOB) (Table S3 in the Supplementary Appendix). CSF denotes cerebrospinal fluid, and SUVR standardized uptake
value ratio.
†		 Scores on the CDR-SOB range from 0 (cognitive normality) to 18 (maximal cognitive impairment).
‡		 P<0.01.
§		 P<0.001.
¶		 Scores on the Mini–Mental State Examination (MMSE) range from 0 (severe impairment) to 30 (no impairment). A score higher than 27
is considered normal.
‖		 Scores on the Logical Memory subtest of the Wechsler Memory Scale–Revised range from 0 (no recall) to 25 (complete recall).
** P<0.05.
†† Deposition of amyloid-beta (Aβ) in the precuneus was measured by positron-emission tomography (PET) with the use of Pittsburgh compound B (PIB). A higher SUVR indicates greater binding of PIB to fibrillar amyloid.
‡‡ Glucose metabolism in the precuneus was measured by PET with the use of fluorodeoxyglucose. A lower SUVR indicates lower metabolism.

with 40 PSEN1, 3 PSEN2, and 8 APP pedigrees.20 As
expected with an autosomal dominant inheritance
pattern, approximately 50% of the asymptomatic
participants were mutation carriers. There were no
significant differences in the presence of an APOE
ε4 allele or sex between asymptomatic mutation
carriers and noncarriers. The mean (±SD) age of
parental onset of symptoms was 45.7±6.8 years.
The DIAN parental age of symptom onset was correlated with the age of symptom onset for symptomatic offspring (Pearson correlation coefficient,
0.56; P<0.001).
CLINICAL and NEUROPSYCHOMETRIC FINDINGS

We measured clinical impairment with the use
of the Clinical Dementia Rating–Sum of Boxes
(CDR-SOB), with scores ranging from 0 (cognitive
normality) to 18 (maximal cognitive impairment).

n engl j med 367;9

Significant differences in CDR-SOB scores were
detected between mutation carriers and noncarriers 5 years before expected symptom onset (Fig. 1A
and Table 2). Noncarriers had stable CDR-SOB
scores of 0 throughout the relative age range,
whereas carriers had increasing CDR-SOB scores
at higher values of estimated years from expected
symptom onset. In this cohort, participants had a
CDR rating of mild dementia (CDR 1) at a mean
of 3.3±5.3 years after the parent’s age of symptom onset.
Significant differences in MMSE scores between mutation carriers and noncarriers were detected at assessments performed 5 years before
expected symptom onset; carriers had decreasing
MMSE scores at higher values of estimated years
from expected symptom onset (Fig. 1B). We found
significant cognitive impairment in mutation car-
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Noncarriers

A Clinical Dementia Rating–Sum of Boxes
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Carriers

B Mini–Mental State Examination

C Logical Memory
20

30

4

25

2
0
−2

20
15

−10

0

10

20

−30

D Hippocampal Volume

SUVR

mm3

9,000

7,000
6,000
−30

−20

−10

−10

0

10

20

0

10

20

G CSF Tau

pg/ml

50
0
−20

−10

0

10

20

Estimated Yr from Symptom Onset

0

10

20

1.0
0.8
0.6
0.4

−20

−10

0

10

20

H CSF Aβ42

100

−10

1.2

−30

Estimated Yr from Symptom Onset

200

−20

Estimated Yr from Symptom Onset

1.4

−30

250
150

−30

F Aβ Deposition in the Precuneus

2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0

Estimated Yr from Symptom Onset

−30

−20

E Glucose Metabolism in the Precuneus

10,000

8,000

5

Estimated Yr from Symptom Onset

SUVR

−20

Estimated Yr from Symptom Onset

10

0

−10

0

10

20

I Plasma Aβ42

700
600
500
400
300
200
100
−30

−20

Estimated Yr from Symptom Onset

pg/ml

−30

pg/ml

15

Score

6

Score

Score

8

−20

−10

0

10

55
50
45
40
35
30
25

20

Estimated Yr from Symptom Onset

−30

−20

−10

0

10

20

Estimated Yr from Symptom Onset

Figure 1. Cross-Sectional Analyses of Clinical, Cognitive, Structural, Metabolic, and Biochemical Changes in Autosomal Dominant
Alzheimer’s Disease Mutation Carriers versus Noncarriers, According to Estimated Years from Expected Symptom Onset.
The clinical and cognitive measures of the Clinical Dementia Rating–Sum of Boxes (scores range from 0 [cognitive normality] to 18 [maximal
cognitive impairment]) (Panel A), the Mini–Mental State Examination (scores range from 0 [severe impairment] to 30 [no impairment])
(Panel B), and the Logical Memory subtest of the Wechsler Memory Scale–Revised (scores range from 0 [no recall] to 25 [complete recall])
(Panel C) showed impaired ratings beginning approximately 5 to 10 years before expected symptom onset. MRI measures of hippocampal
volume (Panel D) showed increased brain atrophy approximately 15 years before expected symptom onset. Decreases in cerebral glucose
metabolism, as measured by positron-emission tomography (PET) with the use of fluorodeoxyglucose (Panel E), occurred approximately
10 years before expected symptom onset, and deposition of amyloid-beta (Aβ) in the precuneus, as measured by PET with the use of Pittsburgh compound B (Panel F), began approximately 15 to 20 years before expected symptom onset. In the cerebrospinal fluid (CSF), levels
of tau protein (Panel G) increased beginning 10 to 15 years before expected symptom onset, and levels of Aβ42 (Panel H) decreased at least
15 years before expected symptom onset. Plasma Aβ42 levels were elevated throughout the range of estimated years from expected symptom
onset (Panel I). Dashed lines represent 95% confidence intervals of the fitted curves. SUVR denotes standardized uptake value ratio.

riers, as compared with noncarriers, in the delayed-recall portion of the Logical Memory test21
10 years before expected symptom onset (Table 2).
Noncarriers remained stable in performance
from 30 years before to 20 years after expected
symptom onset (Fig. 1C).

800

n engl j med 367;9

BRAIN ATROPHY

MRI structural measures of hippocampal volume
were compared between mutation carriers and
noncarriers with the use of an a priori hypothesis
of increased atrophy in mutation carriers. Increased atrophy of bilateral hippocampi was de-
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tected in mutation carriers 15 years before expected symptom onset (Table 2). As expected, there
was an age-dependent decrease in hippocampal
volumes in noncarriers (Fig. 1D).22
FDG-PET measures of cerebral glucose use in the
precuneus were compared with the use of an a
priori hypothesis of decreased metabolism in
mutation carriers to determine regional metabolic
defects. The precuneus region, which is known
to be an area of early deposition in both sporadic
Alzheimer’s disease and autosomal dominant Alz
heimer’s disease,4,23,24 was chosen for analysis of
amyloid deposition. A significant decrease in cerebral metabolism in the precuneus was detected in
mutation carriers 10 years before expected symptom onset (Fig. 1E and Table 2).
A β DEPOSITION

PIB-PET measures of fibrillar Aβ deposition25 in
the precuneus were compared with the use of an
a priori hypothesis of increased regional amounts
of amyloid deposition in mutation carriers. There
was no detectable amyloid deposition in noncarriers. All noncarriers had PIB-PET SUVR values of
less than 0.88. As compared with noncarriers,
mutation carriers had significant amyloid deposition in the precuneus 15 years before expected
symptom onset (Fig. 1F and Table 2). The amount
of amyloid deposition in mutation carriers increased as a function of estimated years from expected symptom onset at least until clinical symptom onset.
BIOCHEMICAL MEASURES

In mutation carriers, levels of tau in the CSF were
increased 15 years before expected symptom onset
(Fig. 1G and Table 2). Concentrations of Aβ42 in
the CSF decreased as a function of estimated years
from expected symptom onset and were pseudonormal at approximately 20 years before expected
symptom onset, reaching low levels 10 years before expected symptom onset (Fig. 1H). The decrease by half in Aβ42 in the CSF and the increase
in tau in the CSF were similar in magnitude to
those typically observed in late-onset sporadic Alz
heimer’s disease.26 Plasma Aβ42 levels were elevated in mutation carriers, as compared with noncarriers (Fig. 1I).
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Figure 2. Comparison of Clinical, Cognitive, Structural, Metabolic, and
Biochemical Changes as a Function of Estimated Years from Expected
Symptom Onset.
The normalized differences between mutation carriers and noncarriers are
shown versus estimated years from expected symptom onset and plotted
with a fitted curve. The order of differences suggests decreasing Aβ42 in
the CSF (CSF Aβ42), followed by fibrillar Aβ deposition, then increased tau
in the CSF (CSF tau), followed by hippocampal atrophy and hypometabolism, with cognitive and clinical changes (as measured by the Clinical Dementia Rating–Sum of Boxes [CDR-SOB]) occurring later. Mild dementia
(CDR 1) occurred an average of 3.3 years before expected symptom onset.
95% confidence interval bands are shown in Figure S2 in the Supplementary
Appendix.

COMBINED MODEL

The order and rate of pathophysiological changes
in autosomal dominant Alzheimer’s disease were
estimated with the use of an analysis of the relationship among clinical, cognitive, imaging, and
biochemical measures in the DIAN cohort (Fig. 2).
Beginning 25 years before expected symptom onset, Aβ42 concentrations in the CSF in mutation
carriers appeared to decline, as compared with
those in noncarriers. Aβ deposition as measured
by PIB-PET (Fig. 3; and see Video 1, available at
NEJM.org) was detected at least 15 years before
expected symptom onset (Table 2). Increases in
levels of tau in the CSF and in brain atrophy were
detected approximately 15 years before expected
symptom onset, followed by cerebral hypometabolism and impaired episodic memory approximately 10 years before expected symptom onset and
global cognitive impairment starting at 5 years
before expected symptom onset.
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A video showing
Aβ deposition over
time is available
at NEJM.org
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Figure 3. Aβ Deposition in Autosomal Dominant Alzheimer’s Disease Years
before Expected Clinical Symptoms.
Panel A compares the fibrillar Aβ deposition, as measured by PET with the
use of Pittsburgh compound B (PIB), of the average of autosomal dominant
Alzheimer’s disease mutation carriers and noncarriers 20 years before the
estimated time of onset of symptoms. There was significant Aβ deposition
in the caudate and cortex in mutation carriers more than 10 years before
expected symptom onset, as compared with noncarriers (Panel B). Panel C
shows additional Aβ deposition throughout the cortex and neostriatum at
the estimated time of symptom onset. An increased SUVR indicates increased
binding of PIB to fibrillar amyloid. The scale ranges from low SUVR values
(bluer colors), indicating low amounts of amyloid, to high SUVR values
(redder colors), indicating high amounts of amyloid.

Discussion
Previous studies of autosomal dominant Alzhei
mer’s disease have showed hippocampal atrophy,27
fibrillar amyloidosis,28 and biochemical abnormalities in the CSF.29 With the establishment of
DIAN, a worldwide network of autosomal dominant Alzheimer’s disease centers, we have estimated the timing and order of changes in autosomal
dominant Alzheimer’s disease in a large cohort
with the disease. Changes begin in the brain at
least two decades before the estimated onset of
clinical symptoms. With the use of estimates of
years from expected symptom onset, the order
and magnitude of changes indicate that genetic
mutations cause increased Aβ42, which is followed by brain amyloidosis, tauopathy, brain atrophy, and decreased glucose metabolism. After
these biologic changes, cognitive impairment can
be detected, which culminates in clinical impairment and eventually dementia. These findings
suggest that the diagnosis of clinical dementia is
made late in the course of the biologic cascade of
autosomal dominant Alzheimer’s disease.
The estimated year from expected symptom
onset normalizes the stage of disease on the
802
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basis of the parental age of onset. Our findings
suggest that once initiated, Alzheimer’s disease
processes are likely independent of absolute age
but rather depend on the start of processes such
as Aβ misfolding and other modulating factors.
Furthermore, other findings suggest that amyloid deposition probably occurs years or decades
before dementia symptoms are manifest in sporadic Alzheimer’s disease.24 Previous cross-sectional studies in sporadic Alzheimer’s disease
have suggested a series of changes that lead to
clinical disease.2 Our results support the hypothesis of a pathophysiological cascade and
suggest the possibility of a common pathophysiology between autosomal dominant Alzhei
mer’s disease and the much more common
“sporadic” form.
A strength of this study is that it shows relative changes in Alzheimer’s disease processes that
occur over a period of four decades. However,
interpretations of the results are not certain,
because the current analyses are based on crosssectional data, which do not represent individual
longitudinal changes. In addition, although
many of our findings in autosomal dominant
Alzheimer’s disease are similar to findings in
sporadic Alzheimer’s disease, there were some
differences. For example, trends for increased
levels of Aβ42 in the CSF have not been reported
in sporadic Alzheimer’s disease or autosomal
dominant Alzheimer’s disease, although this
trend was predicted in autosomal dominant Alz
heimer’s disease, because familial Alzheimer’s
disease mutations cause increased Aβ or Aβ42
production.30 Furthermore, unlike sporadic Alzhei
mer’s disease, autosomal dominant Alzheimer’s
disease typically presents with early and pronounced PIB-PET signaling in the neostriatum.28
Although the findings of this study were largely
based on PSEN1 mutations, a comparison with
PSEN2 and APP mutations (Table S2 in the Supplementary Appendix) suggests no differences in
results among the mutation gene types. Owing
to the younger age of the cohort, the prevalence
of confounders such as vascular risk factors was
low (<15%) in this cohort and not significantly
different between carriers and noncarriers. Although the clinical and pathologic phenotypes of
dominantly inherited Alzheimer’s disease are
similar to those of sporadic Alzheimer’s disease,
the generalizability of the nature and sequence
of brain changes in autosomal dominant Alzhei
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mer’s disease remains to be determined for sporadic Alzheimer’s disease.
The definition of the timing and magnitude
of pathophysiological changes associated with
Alzheimer’s disease has implications for the development and implementation of diagnostic and
predictive tests and the design of prevention trials.31 For example, our data suggest that amyloid
deposition will develop and be detectable in all
persons with a mutation while still asymptomatic, whereas no noncarriers had positive scans for
amyloid deposition. If autosomal dominant Alz
heimer’s disease is similar to late-onset Alz
heimer’s disease, this finding suggests that
Alzheimer’s dementia will eventually develop in
persons with positive scans for amyloid deposition. These findings suggest that the targeting of
Aβ earlier in the course of the disease may provide better clinical outcomes than the treatment

of mild to moderate dementia after substantial
neuronal and synaptic loss has occurred.32
In summary, our findings indicate that the
Alzheimer’s disease process begins more than
20 years before the clinical onset of dementia.
Treatment and prevention trials can incorporate
these pathophysiological changes to gauge the
likelihood of future clinical success. Secondary
prevention trials that are designed to prevent or
delay cognitive and clinical impairment may ultimately test the amyloid hypothesis, just as the
cholesterol hypothesis of heart disease was tested
three decades ago.33
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